How are energy investors positioned?
Furthermore, Bruker (NASDAQ:BRKR)’s TwinScape™ has emerged as a cloud-based, AI-enabled proteomics quality monitoring solution, which is now monitoring hundreds of customer systems. It has been recognized for improving workflow efficiency and providing proactive technical customer support.These advancements reflect Bruker’s commitment to enhancing the capabilities of life science researchers and supporting innovations that improve human health. While the company’s stock currently trades near its 52-week low of $48.07, InvestingPro analysis reveals 8 additional key investment insights and a comprehensive Pro Research Report, which transforms complex Wall Street data into actionable intelligence for smarter investing decisions. The information for this article is based on a press release statement.
The company introduced the Athena Ion Processor (AIP) on the timsTOF Ultra 2 system, which is expected to improve protein group identification in single-cell proteomics by 15%-20% and peptide identifications by 20%-25%. The AIP is designed to efficiently transfer ions, resulting in greater sequence coverage, and is set to be launched at ASMS 2025 with field upgradability for the timsTOF Ultra 2 system.
Additionally, Bruker announced the integration of the DeutEx™ software, developed by Petr Novák of the Czech Academy of Sciences, into its proteomics ecosystem. DeutEx is intended to support various Bruker systems and enhance the study of structural and dynamic properties of proteins for biopharma research and structural biology.
OmniScape™ 2025b software was also introduced, offering a tenfold increase in de novo sequencing performance and improved top-down proteomics analysis. This software is praised for its user-friendly interface and interactive fragment assignment capabilities, aiding in the validation of protein sequences and post-translational modifications.
The company has updated its ProteoScape™ platform, with Spectronaut® and GlycoScape™ software enhancements that increase the number of identified glycopeptides by 6-10 times. This aids in high-throughput glycoform profiling and is compatible with timsTOF systems.
Furthermore, Bruker’s TwinScape™ has emerged as a cloud-based, AI-enabled proteomics quality monitoring solution, which is now monitoring hundreds of customer systems. It has been recognized for improving workflow efficiency and providing proactive technical customer support.
These advancements reflect Bruker’s commitment to enhancing the capabilities of life science researchers and supporting innovations that improve human health. The information for this article is based on a press release statement.
In other recent news, Bruker Corporation reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.76, compared to the forecast of $0.74. The company also exceeded revenue projections, achieving $979.6 million against the expected $962.38 million, marking a 14.6% year-over-year increase in quarterly revenue. The company’s guidance for 2025 anticipates revenue growth between $3.47 billion and $3.54 billion, with an expected constant exchange rate growth of 5-7%. Additionally, Bruker has appointed Laura Francis as an independent director to its board, with plans for her to join the Audit Committee as a financial expert following the annual shareholder meeting. Francis brings extensive experience from her roles at SI-BONE, Inc. and other notable organizations. Meanwhile, Bruker continues to focus on strategic acquisitions and innovation, which have bolstered its competitive position in key markets such as semiconductor metrology and microbiology. The company’s management is optimistic about a gradual recovery in the biopharma sector and is managing uncertainties related to NIH funding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.